Retatrutide vs Liraglutide
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
| Attribute | Retatrutide | Liraglutide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / GLP-1 Agonist |
| Evidence Rating | B — Phase III / NDA Filed | A — FDA Approved |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | FDA-approved (Victoza for T2D, Saxenda for obesity) |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). This triple synergy combines reduced cal... | Liraglutide binds to GLP-1 receptors on pancreatic β-cells, increasing intracellular cAMP and triggering glucose-dependent insulin secretion. It suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake and increase satiety. A fatty acid (C1... |
| Half-Life | ~6 days (allows once-weekly dosing) | ~13 hours |
| Bioavailability | SC injection | ~55% SC |
| Molecular Weight | — | ~3,751 g/mol |
| WADA Status | Not Prohibited | Not Prohibited |
| Research Half-Life | ~6 days (allows once-weekly dosing) | ~13 hours |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Phase 3 TRIUMPH program ongoing (Eli Lilly). TRIUMPH-4 reported 28.7% body weight loss at 12 mg over 68 weeks. Seven Phase 3 readouts expected in 2026. Regulatory submission expected 2026; approval anticipated 2027-2028. | FDA-approved: Victoza (T2D, 2010), Saxenda (obesity, 2014). Prescription only. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Retatrutide | Liraglutide |
|---|---|---|
| Purity Standard | ≥98% | — |
| CAS Number | 2381089-83-2 | — |
| Molecular Formula | C₂₂₅H₃₄₈N₆₀O₆₈S₂ | — |
| Available Formats | 20mg, 10mg | — |
| Batch COAs Published | 2 on file | — |
| Stock Status | In stock | — |
Availability at Volta Peptides
Retatrutide 20mg
≥98% purity · HPLC verified · In stock
$99
Liraglutide
Not currently stocked at Volta Peptides.
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.